NASDAQ:BLU
Delisted
Bellus Health Inc. Stock Company Profile
$14.74
+0 (+0%)
At Close: Sep 27, 2023
Information
275 Armand-Frappier Boulevard
Laval QC H7V 4A7
www.bellushealth.com
Industry: Biotechnology
Sector: Healthcare
Description
BELLUS Health Inc., a clinical stage biopharmaceutical company, develops therapeutics for the treatment of refractory chronic cough (RCC) and other cough hypersensitivity indications. Its lead product candidate includes BLU-5937, an antagonist of the P2X3 receptor, which is in Phase II clinical trial for treatment of RCC and chronic pruritus. The company was incorporated in 1993 and is based in Laval, Canada.
